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A double-blind, randomized, placebo-controlled 
pilot trial to determine the efficacy and safety  
of ibudilast, a potential glial attenuator,  
in chronic migraine
Yuen H Kwok1 
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Parisa Gazerani2 
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Medical School North, South 
Australia, Australia; 2Department of 
Health Science & Technology, Aalborg 
University, Aalborg, Denmark 
Background: Chronic migraine (CM) is problematic, and there are few effective treatments. 
Recently, it has been hypothesized that glial activation may be a contributor to migraine; there-
fore, this study investigated whether the potential glial inhibitor, ibudilast, could attenuate CM. 
Methods: The study was of double-blind, randomized, placebo-controlled, two-period crossover 
design. Participants were randomized to receive either ibudilast (40 mg twice daily) or placebo 
treatment for 8 weeks. Subsequently, the participants underwent a 4-week washout period 
followed by a second 8-week treatment block with the alternative treatment. CM participants 
completed a headache diary 4 weeks before randomization throughout both treatment periods 
and 4 weeks after treatment. Questionnaires assessing quality of life and cutaneous allodynia 
were collected on eight occasions throughout the study. 
Results: A total of 33 participants were randomized, and 14 participants completed the study. 
Ibudilast was generally well tolerated with mild, transient adverse events, principally nausea. 
Eight weeks of ibudilast treatment did not reduce the frequency of moderate to severe headache 
or of secondary outcome measures such as headache index, intake of symptomatic medications, 
quality of life or change in cutaneous allodynia. 
Conclusion: Using the current regimen, ibudilast does not improve migraine with CM 
participants.
Keywords: chronic migraine, glia, ibudilast, headache, immune system
Introduction 
Chronic migraine (CM) is a disabling and undertreated disorder1 which represents 
a clinically challenging problem that impacts significantly on the quality of life of 
affected individuals and imposes a large economic burden upon society due to lost 
productivity.2,3 Despite this burden, the pathophysiology behind migraine and especially 
the processes of migraine chronification remain poorly understood. A growing body of 
preclinical and clinical evidence suggests that acquired sensitization plays a significant 
role in the pathology of migraine and the process of chronification.4 
Recent evidence supports the importance of neuronal–glial interactions as a 
potential mechanism for chronic pain. Glia are located in the central nervous system, 
and under basal condition, they perform housekeeping functions and maintain neural 
homeostasis.5 However, when glia are activated, they become immunoresponsive 
and modulate pain by releasing neuroexcitatory signals that can increase neuronal 
excitability,6,7 activate neighboring glia, and produce nociceptive mediators (such as 
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nitric oxide, excitatory amino acids, and proinflammatory 
cytokines).8 
Nonclinical models support a role of neuron–glia inter-
actions in the initiation of migraine attacks, as glia have 
been shown to release a range of inflammatory cytokines 
and chemokines in animal models evoking some features of 
migraine.9 In nonclinical models, blockade of glial activa-
tion and proinflammatory mediators released by glia caused 
reduction in hypersensitivity and allodynia, respectively.10,11 
Additionally, a clinical study has reported elevated levels of 
proinflammatory cytokines in the cerebrospinal fluid of CM 
participants.12 Such tonically increased glial activity may 
underlie the progression from episodic to CM.13 Furthermore, 
in a separate study, levels of the chemokine interleukin 8 were 
found to be elevated in the jugular venous blood of patients 
during a migraine attack.14 Interleukin 8 can be synthesized 
by glia in response to other proinflammatory mediators 
including tumor necrosis factor α, lending additional support 
to the neurogenic inflammation model of migraine.15
Thus, it seems likely that nociceptive signaling during 
migraine attacks releases mediators that activate glia. Acti-
vated glia then release a range of proinflammatory mediators 
such as cytokines, chemokines, reactive oxygen species, and 
prostaglandins, which not only facilitate pain transmission 
but also activate further glia, creating a positive feedback 
loop. After a stimulus is resolved, experimental evidence 
suggests that microglia may remain “primed,” entering a 
state in which they do not actively produce proinflammatory 
substances, yet they over-respond to subsequent stimuli, 
resulting in increased proinflammatory cytokine release 
and an exaggerated pain response.16 This could lead to an 
increase in migraine frequency as triggers that were previ-
ously subthreshold may now initiate headache.
Although glial involvement in the pathogenesis of migraine 
and in the transformation of episodic migraine to CM has been 
suggested by a number of authors,9,13,17–19 to our knowledge no 
treatments targeting this mechanism have been trialed specifi-
cally in high frequency migraineurs. However, encouraging 
results from an open-label retrospective study in participants 
with varying chronic daily headache phenotypes following 
treatment with the potential glial attenuator minocycline have 
been reported.20 This study, published only in abstract form, 
found a significant decrease in headache frequency follow-
ing 2 months of minocycline administration when used as an 
adjunctive preventative medication.20 However, the efficacy of 
minocycline in animal studies, suggests that it is only effective 
before chronic pain is established and not subsequently,10 which 
may not be applicable to chronic pain patients. 
Ibudilast is a nonselective phosphodiesterase inhibitor 
that has been used in Japan for 20 years to treat bronchial 
asthma,21 post-stroke dizziness,22 and ocular allergies.23 
Ibudilast inhibits tracheal smooth muscle contractility24 and 
platelet aggregation,25 improves cerebral blood flow,22 and 
attenuates allergic reactions.26,27 
As ibudilast is administered orally, is well tolerated, and 
has good blood–brain barrier permeability,28–30 it is a suitable 
candidate for the treatment of chronic pain. In nonclinical 
models, ibudilast attenuated microglial activation (reduced 
withdrawal behaviors), reduced production of proinflamma-
tory cytokines, enhanced the production of anti-inflammatory 
cytokines, and improved the safety profile of opioids (reduced 
tolerance and attenuated reward and dependence).23,31–33 
Moreover, ibudilast exhibited immunomodulatory actions 
in multiple sclerosis patients30 and also displayed inhibition 
of proinflammatory cytokines from peripheral leukocytes.34 
In the present study, the efficacy of the putative glial 
attenuator ibudilast in participants with high frequency 
migraine was investigated. The study investigated the efficacy 
of ibudilast on the frequency of moderate to severe head-
ache and other headache indices (such as headache index, 
headache-related questionnaires, and acute symptomatic 
medication intake) in CM patients over 8 weeks of ibudilast 
treatment compared with placebo treatment. 
Methods
Study approval 
Ethical approval was obtained from the Human Research 
Ethics Committee of the Royal Adelaide Hospital, Adelaide, 
South Australia. All the participants gave their written 
informed consent before the commencement of the study. The 
study was conducted at the Pain and Anaesthesia Research 
Clinic, Royal Adelaide Hospital, Adelaide, Australia, and in 
accordance with the Principles of International Conference 
on Harmonization Good Clinical Practice, the Declaration of 
Helsinki, and the Australian National Statement on Ethical 
Conduct in Research Involving Humans. 
The study was of double-blind, randomized, placebo-con-
trolled, two-period crossover design. Participants were random-
ized to initially receive either ibudilast or placebo treatment for 8 
weeks. Subsequently, the participants underwent a 4-week wash-
out period followed by a second 8-week treatment block with 
the alternative treatment (Clinicaltrials.gov NCT01389193). 
Participant selection
Participants were recruited from June 2013 to May 2015. 
Criteria for CM were defined by the revised second edition 
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of the International Classification of Headache Disorders 
(ICHD-II).35 Key inclusion criteria were:
1. Men and women aged between 18 and 65 years
2. Migraine with or without aura, as diagnosed according 
to the ICHD-II36
3. Onset of migraine before 50 years of age
4. Headache for ≥15 days per month
5. Migraine-like headache for ≥8 days per month, as per the 
International Headache Society (IHS) guidelines37
Key exclusion criteria 
Participants were excluded from the study on the basis of 
the following criteria: change in type or dose of migraine 
prophylactic medication in last 3 months, medication over-
use headache as diagnosed according to the ICHD-II35, 
posttraumatic headache as diagnosed according to the 
ICHD-II36, another dominant chronic pain condition, an 
active inflammatory disease such as rheumatoid arthritis, a 
history of recent cerebrovascular disorder, inability to pro-
vide written informed consent, inability to read and write 
in English, presence of severe psychological/psychiatric 
disorders, recent history of significant trauma, recent his-
tory of drug or alcohol abuse, clinically significant findings 
on screening blood sample results, current malignancy, 
known hypersensitivity to ibudilast or excipients in Ketas® 
formulation, renal or hepatic impairment, pregnancy, lack 
of adequate contraception, and breastfeeding.
Study medication
The study used a delayed-release ibudilast product, Ketas®, 
which was obtained from Kyorin Pharmaceuticals Industries, 
Ltd (Tokyo, Japan). To blind the treatment allocation, the 
Ketas® capsule was overencapsulated with the space filled 
with microcrystalline cellulose. The placebo capsule was 
of the same size and color and filled with microcrystalline 
cellulose, so that the active and placebo medications were 
identical in appearance and weight. Each active capsule con-
tained 10 mg ibudilast. Four capsules were self-administered 
by participants orally, twice daily for each 8-week treatment 
block. No treatment was administered during the washout.  
Study schedule
4 weeks prior to baseline visit 
At screening, potential participants underwent,
•	 Medical history including medication history
•	 Headache diagnosis based upon retrospective information 
from the participant confirmed using baseline headache 
diary data
•	 Completion of the Hospital Anxiety and Depression Scale 
•	 Physical examination 
•	 Urine pregnancy test for women of childbearing potential
•	 Urine drug screen to rule out the presence of nonpre-
scribed drugs of abuse
•	 Blood samples to assess hematology (4 mL), biochemistry 
including renal function and hepatic function (8 mL).
After successful completion of the screening visit and confir-
mation of study eligibility, participants were provided with a 
headache diary to complete at least 4 weeks prior to the base-
line visit to confirm study eligibility. Standardized education 
and instructions on how to complete the diary was provided 
by the experimenter, and the participants were required to fill 
in the headache diary daily. The headache diary recorded a 
comprehensive assessment of the headache experienced by 
participants and consisted of head pain characteristics, head-
ache frequency, average headache intensity (11-point numeri-
cal rating scale), duration of headache (number of hours), 
and intake of symptomatic headache treatments (timing, 
type, and amount of medication consumed). The headache 
index was calculated by the summation of headache duration 
(hours) with headache intensity (11-point numerical rating 
scale). The dose of opioid-containing analgesics used by each 
patient was converted to oral morphine equivalent dose based 
on the local Royal Adelaide Hospital Pain Management Unit 
opioid conversion table. 
Baseline visit 
During the baseline visit, the headache diary was collected, 
and participants who were eligible to continue in the study 
were randomized to either ibudilast or placebo treatment 
in the first period. Participants were asked to complete two 
brief self-administered questionnaires. The 6-point Headache 
Impact Test (HIT-6) evaluated the impact of headache on the 
quality of life, reflecting upon the previous month,38 and the 
12-point Allodynia Symptom Checklist (ASC-12) indicated 
whether, and quantified how, increased pain sensitivity 
impacted upon activities of day-to-day life.39
About 14 mL of blood was collected to assess safety 
blood profile (blood biochemistry [including the assessment 
of renal function], liver function tests and  hematology). 
Participants were advised to take only the minimum amount 
of medications required to control their pain; however, 
they were not specifically informed to reduce their anal-
gesic intake. Participants were asked to complete another 
headache diary for the 8-week treatment period. The study 
medication was dispensed to the participants prior to 
discharge.
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Participants were required to complete the headache diary 
throughout the two treatment periods, during the washout 
phase and for 4 weeks after ceasing the study medication. 
In study visits
Inspection of headache diary, assessment of adverse events, 
completion of questionnaires, and safety bloods were taken at 
weeks 2, 4, and 8 of each period. Figure 1 shows the flowchart 
of the study design. 
Statistical analysis 
All the participants who received at least one dose of the study 
medication were included in the safety population. However, 
the efficacy data were only analyzed for completers, given 
the crossover nature of the trial.
Graphpad Prism 6.0 (GraphPad Software; San Diego, 
CA, USA) was used for all statistical analysis. The Wilcoxon 
matched pairs signed rank test was used to calculate the study 
medication adherence between the CM participants while 
in different treatment groups. Two-way analysis of variance 
tests with repeated measures and with Sidak adjustments 
were used to determine the differences between treatments 
in multiple comparisons were used to calculate frequency of 
moderate to severe headache experienced, headache index, 
frequency of symptomatic medication intake, average opioid 
intake, HIT-6 scores, and ASC-12 scores. Missing values 
were replaced by the last observed value for that variable 
(last observation carried forward). All results are presented 
as mean ± standard deviation (SD) unless stated otherwise. 
Significance was set at P<0.05. 
Results 
Demographics of CM participants 
A total of 33 patients were randomized to treatment. Fourteen 
CM participants completed both the treatments of the study 
and returned completed headache diaries suitable for analysis. 
Four CM participants completed both the treatments of the 
study but did not return adequate diaries for analysis and 
therefore were excluded from the analysis (Figure 2). 
Fifteen participants (nine received ibudilast) did not 
complete the study and hence were also excluded from the 
analysis. Of these fifteen participants, two participants lost 
interest in the study; one was excluded due to work commit-
ment; four were excluded because of loss to follow-up; one 
was excluded as that participant had changed his medica-
tion; one was excluded after receiving 1 week of treatment 
as she was found to be pregnant (she was on placebo); one 
was excluded after experiencing heart palpitation; four 
participants were withdrawn by the investigator because of 
worsening headaches; and one participant was excluded by 
the investigator as the patient experienced tingling sensation. 
Demographics of the participants are listed in Table 1. 
The mean age was 46 years (SD 13). The study consisted of 
11 men and 22 women. The average duration of headache 
was 21 years (SD 15). The mean daily morphine equivalent 
dose was 4.2 mg (SD10). 
Compliance to study medication and 
safety 
In this study, all the participants had good adherence to study 
medications as demonstrated with the return of unused study 
capsules. There was no treatment group difference (P=0.6) 
with the number of capsules returned (placebo vs ibudilast 
[mean {SD}: 2.4 {2.4} vs 7.7 {15.6}]). 
Adverse events experienced in the study were of mild inten-
sity, and all the reported adverse events are listed in Table 2. 
Seventeen of the twenty-three (60%) CM participants who 
were on ibudilast treatments reported adverse events, whereas 
eight of the twenty-three (35%) CM participants reported 
adverse events during placebo treatments. The most frequent 
Screening visit
Week: –3 To 0: Baseline headache diary
Week 1: Baseline visit – Randomization to group
Weeks 1–8: Ibudilast or placebo 
·Study visits at weeks 2, 4, and 8 
  ·Headache diary each day
Weeks 9–12: Washout headache diary 
Week 13 visit – Crossover to alternative treatment 
Weeks 13–20: Placebo or ibudilast 
·Study visits at weeks 14, 16, and 20 
  ·Headache diary each day
Weeks 21–24: Follow up headache diary  
Figure 1 Study overview. 
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Responders to advertisements
n=543
Attended initial screening session
n=73
Full screening 
n=43
Failed initial screening 
n=30
Failed full screening 
n=30
Withdrew during treatment 
n=15
Passed full screening &
randomized to treatment 
n=33
Completed both the periods of trial
(included in data analysis) 
n=14
Completed both the periods of trial
but did not return study 
documents
n=4
Figure 2 Flow diagram of numbers of participants in different phases of the study.
Table 1 Demographics of CM participants 
Study population Mean SD
Randomized population
 Demographics (n=33)
 Age (years) 45.8 12.5
 Sex: male (n) 11
 HADS – anxiety score 6.16 3.08
 HADS – depression score 3.94 2.73
 Age at onset of headache disorder (years) 25.1 11.7
 Headache disorder duration (years) 20.8 14.6
 Daily morphine usage (mg) 4.2 10.1
Completers
 Demographics (n=14)
 Age (years) 50 12.6
 Sex: male (n) 4
 HADS – anxiety score 5.5 2.7
 HADS – depression score 3.7 2.1
 Age at onset of headache disorder (years) 28 12.1
 Headache disorder duration (years) 22 14
 Daily morphine usage (mg) 4.6 13.2
Abbreviations: CM, chronic migraine; HADS, Hospital Anxiety and Depression 
Scale; SD, standard deviation.
adverse event in both the groups was worsening migraine, 
reported by 4/28 under ibudilast and 2/23 on placebo. The next 
most frequently reported adverse event was nausea, reported 
by 4/28 under ibudilast and by no participant on placebo.
Headaches
When CM participants were on ibudilast treatment, they 
did not experience reduced frequency of moderate to severe 
headache compared with placebo treatment (P=0.9) in either 
treatment weeks 1–4 (mean difference –0.9, 95% confidence 
interval [CI] –9.1 to 7.3) or treatment weeks 5–8 (mean dif-
ference 0.1, 95% CI –8.1 to 8.3). However, irrespective of 
treatments, in treatment weeks 5–8 of each block, there was 
a significant reduction (P=0.02) in the frequency of moderate 
to severe headaches (Figure 3).
Likewise, when CM participants were on ibudilast treat-
ment, they did not experience a reduction in headache index 
when compared with placebo treatment (P=0.9) in either treat-
ment weeks 1–4 (mean difference –5.7, 95% CI –56.6 to 45.2) 
or treatment weeks 5–8 (mean difference –0.4, 95% CI –51.3 to 
50.5). However, in treatment weeks 5–8, there was a significant 
reduction in the headache index (P=0.003) (Figure 4). 
Acute symptomatic medication intake 
and self-reported questionnaires
No treatment differences were detected in the frequency 
intake of symptomatic medication (P=0.6) in either treat-
ment weeks 1–4 (mean difference –2.6, 95% CI –11.7 
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Table 2 AEs reported by CM participants (n=33) during treatment
Number of participants 
experiencing an AE
Ibudilast Placebo
Total (n=28) 
n (%)
Possibly or probably related  
to study medication (%)
Total (n=23)
n (%)
Possibly or probably related 
to study medication (%)
Gastrointestinal disorders
 Nausea 4 (14) 4 (14) 0 0
 Vomiting 1 (3.5) 1 (3.5) 0 0
 Diarrhea 1 (3.5) 1 (3.5) 1 (4) 1 (4)
 Bloating 1 (3.5) 0 0 0
Nervous system disorders
 Increased frequency of headache 4 (14) 4 (14) 0 0
 Increased frequency of migraine 4 (14) 4 (14) 2 (8.7) 2 (8.7)
 Insomnia 2 (7) 2 (7) 0 0
 Paresthesia 1 (4) 1 (4)
Infections and infestations
 Urinary tract infection 2 (7) 1 (3.5) 0 0
 Bladder infection 2 (7) 1 (3.5) 0 0
 Viral infection/sore throat 2 (7) 0 1 (4) 0
Blood and lymphatic system disorders
 Neutropenia 0 0 1 (4) 0
 Thrombocytopenia 0 0 1 (4) 0
General disorders and 
administration site conditions 
 Heart palpitations 1 (3.5) 1 (3.5) 0 0
 Violent dreams 1 (3.5) 1 (3.5) 0 0
 Vaginal itching 1 (3.5) 1 (3.5) 0 0
 Lethargic 2 (7) 2 (7) 1 (4) 1 (4)
 Lower back pain 1 (3.5) 1 (3.5) 0 0
 Heart burn symptoms 1 (3.5) 1 (3.5) 0 0
 Weight loss 0 0 1 (4) 1 (4)
  Feeling depressed (due to increased 
migraine)
1 (3.5) 1 (3.5) 0 0
Note: Values represent event experienced during two treatment periods.
Abbreviations: AEs, adverse events; CM, chronic migraine.
to 6.6) or treatment weeks 5–8 (mean difference –1.9, 95% 
CI –11 to 7.3) (Figure 5A). The oral morphine equivalent was 
also calculated for the medication that was taken by the CM 
participants; however, no treatment differences were detected 
(P=1) in either treatment weeks 1–4 (mean difference –0.5, 
95% CI –11.2 to 10.2) or treatment weeks 5–8 (mean differ-
ence 0.5, 95% CI –10.2 to 11.2) (Figure 5B). 
Scores on the HIT-6 and ASC-12 questionnaires did not 
differ between the treatment groups during any study time 
period (baseline, weeks 2, 4, and 8 of treatment); P=0.3 and 
P=0.9, respectively (data not shown).
Discussion 
Ibudilast caused no change in the frequency of moderate to 
severe headache when compared with placebo treatment. 
Furthermore, other headache indices such as headache 
index, frequency of acute symptomatic medication intake, 
HIT-6 scores or ASC-12 scores were not reduced when CM 
patients were on ibudilast treatment. Additionally, worsening 
migraine was reported at a higher frequency under ibudilast 
treatment rather than on placebo. However, given the small 
sample sizes used in this study, lack of statistical significance 
should be considered with caution, but there was no trend 
for a benefit with ibudilast. Interestingly, during treatment 
weeks 5–8 of each period, the frequency of moderate to severe 
headache and headache index for both the treatment groups 
were significantly reduced compared to treatment weeks 1–4. 
This observation could be an indicator of participants having 
a positive expectancy of the study drug.40
Even though ibudilast may not be an effective treat-
ment for CM, this study further provides a safety profile of 
ibudilast in a homogeneous migraine cohort. The adverse 
events experienced by participants were mild and transient 
in nature, and most of the adverse events were resolved once 
ibudilast was halted. 
Our results are in agreement with a recently published 
finding by our group, which found ibudilast to have no effect in 
reducing headache index or in reducing opioid intake in medi-
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Ibudilast
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Figure 3 Eight weeks of ibudilast usage did not reduce the frequency of moderate 
to severe headaches.
Notes: CM participants recorded the frequency and intensity of headache 
experience in a diary throughout the course of the study. When the frequency 
of moderate to severe headache experience was averaged over 4-week blocks, 
no significant difference was found between treatments (P=0.9) but a significant 
difference was found between visits (*P=0.02). The values are presented as 
mean ± SD. Headaches were considered to be moderate if participants recorded ≥6 
for “average pain intensity of headache out of 10.” 
Abbreviations: CM, chronic migraine; SD, standard deviation.
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**
1–4 Week 5–8
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Figure 4 Ibudilast did not reduce headache index.
Notes: The daily headache index, averaged over 4-week blocks detected no 
differences between the treatments (P=0.9); however, there was a significant 
reduction in the headache indices at treatment weeks 5–8 compared with treatment 
weeks 1–4 (**P=0.003). The average headache index was calculated by the product 
of headache duration and headache intensity (11-point NRS), averaged over the 
number of days. The values are presented as mean ± SD.  
Abbreviations: NRS, numerical rating scale; SD, standard deviation.
cation overuse headache patients.41 However, the study also 
measured toll-like receptor (TLR) reactivity from peripheral 
blood mononuclear cells and found ibudilast to significantly 
reduce the proinflammatory cytokine (interleukin 1β) levels 
from ex vivo stimulation with TLR-2 or TLR-4 agonists. This 
finding confirmed that ibudilast was likely to be inhibiting 
an inflammatory pathway, at least peripherally. However, the 
peripheral target may be different to the mechanism that is 
responsible for the headache or the treatment period may have 
been insufficient to reverse the long-term changes associated 
with CM or may not have been acting centrally. 
It is unclear from this study whether glia are involved in 
CM. Ibudilast has demonstrated good central nervous system 
partitioning28 but as it was not found to have any effect in the 
clinical endpoints, it suggests that the mechanisms responsible 
for CM may be signaling through another pathway that is cur-
rently unidentified, or neurons may play a stronger role. Thus 
more research would be required to address whether glial 
activation is a likely contributor for CM. The recent demonstra-
tion of imaging of activated glia in patients with chronic low 
back pain provides a potential biomarker for future studies.42
Even though there have been reports of pro- and anti-
inflammatory cytokines being a predictor of headaches, the 
examination of peripheral targets may not be adequate. In a 
CM study, elevation of tumor necrosis factor α was found 
in the cerebrospinal fluid but not in the plasma,12 indicating 
that peripheral biomarkers might not be helpful. 
Limitations
The sample size for this study was small as the required 
number of participants could not be recruited within the time 
frame, so the study ended prematurely (intended target was 
40 CM participants). This was due to the difficulty in finding 
CM participants who fitted the criteria, and this is common 
in research involving chronic headache patients.43,44 
Conclusion
The present study showed ibudilast dosed at 40 mg twice daily 
for 8 weeks is not a promising treatment for CM. However, 
this study adds to the literature of the safety and tolerability 
of ibudilast in a CM cohort, which to our knowledge has not 
been investigated previously. 
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Figure 5 Ibudilast did not reduce the intake of symptomatic medications or the amount of oral morphine equivalent.
Note: (A) There was no difference in the number of days in which symptomatic medication was taken between the treatments (P=0.6) or between visits (P=0.5). (B) There 
were also no treatment (P=1) or visit (P=0.2) differences in the amount of oral morphine equivalent taken between ibudilast or placebo treatments.
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